We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

130 hedge funds and large institutions have $315M invested in ADMA Biologics in 2022 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 33 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

296% more call options, than puts

Call options by funds: $3.82M | Put options by funds: $965K

155% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 11

66% more capital inflows, than outflows

Capital inflows: $64.7M | Capital outflows: $38.9M

30% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 33

15% more funds holding

Funds holding: 113 → 130 (+17)

5.37% more ownership

Funds ownership: 60.72% → 66.09% (+5.4%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
130
Holders Change
+17
Holders Change %
+15.04%
% of All Funds
2.23%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
28
Increased
43
Reduced
33
Closed
11
Calls
$3.82M
Puts
$965K
Net Calls
+$2.86M
Net Calls Change
+$2M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$15.5M
2
Invesco
Invesco
Georgia
+$7.46M
3
Fred Alger Management
Fred Alger Management
New York
+$6.87M
4
Bridgeway Capital Management
Bridgeway Capital Management
Texas
+$5.25M
5
Nuveen
Nuveen
North Carolina
+$3.7M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$9.99M
2
Magnetar Financial
Magnetar Financial
Illinois
-$5.97M
3
Boothbay Fund Management
Boothbay Fund Management
New York
-$5.37M
4
SCM
Stonepine Capital Management
Oregon
-$4.8M
5
ACM
Altium Capital Management
New York
-$2.68M

ADMA Hedge Fund Activity: Q3 2022 in Review

130 of the 5,831 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2022, worth a combined $315M — up 33% from $236M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ADMA positions and 11 closed out — a net gain of 17 holders — while 43 added to existing stakes and 33 trimmed.

The largest buyer was State Street, adding an estimated $15.5M. The largest seller was Millennium Management, cutting an estimated $9.99M.

  • 130 institutional investors held ADMA Biologics (ADMA) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $315M of ADMA Biologics stock for Q3 2022, up 33% quarter-over-quarter.
  • 28 funds opened new ADMA Biologics positions in Q3 2022 and 11 closed out, a net change of +17 holders.
  • The largest ADMA Biologics buyer in Q3 2022 was State Street, an estimated $15.5M added.
  • The largest ADMA Biologics seller in Q3 2022 was Millennium Management, an estimated $9.99M sold.

Based on aggregated 13F filings for Q3 2022.